Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biocept Inc

(NASDAQ: BIOC)
Add to Portfolio
-0.03 (-3.80%)
as of Oct 17, 2019

Last 0.76
Change -0.03 (-3.80%)
Open 0.78
Prev. Close 0.79
Today's Range
0.76
0.80
52wk Range
0.66
3.72
Volume 204,700
Avg Volume 298,455
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
BIOC -3.80% -24.38% -65.75%
DJIA +0.09% +3.92% +5.13%
S&P 500 +0.28% +3.95% +6.72%

Key Statistics

Annual EPS -4.84
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 17,510
Weighted Alpha -73.78
Standard Deviation -1.31
Profit Margin 3.63%
Beta 1.93

Growth Rates

YTD -11.19%
1-Year -66.20%
3-Year -97.07%
5-Year -99.70%

Opinion

Sell Hold Buy

Recent Headlines

Biocept's Target Selector(TM) ctDNA Platform

PR Newswire via COMTEX - Mon Oct 07, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publ(full story)
BIOC: 0.76 (-0.03)

Biocept Announces Issuance of South Korean Patent

PR Newswire via COMTEX - Thu Oct 03, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it (full story)
BIOC: 0.76 (-0.03)

Biocept to Present at Two Investment Conferences in

PR Newswire via COMTEX - Tue Sep 03, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that man(full story)
BIOC: 0.76 (-0.03)

High Sensitivity of Biocept's Target Selector(TM)

PR Newswire via COMTEX - Thu Aug 22, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that cli(full story)
BIOC: 0.76 (-0.03)

Biocept Receives Three Additional Patents Covering its

PR Newswire via COMTEX - Tue Aug 13, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it (full story)
BIOC: 0.76 (-0.03)